OR WAIT null SECS
February 04, 2022
Janssen has submitted a MAA to the EMA for teclistamab as a treatment of relapsed or refractory multiple myeloma (RRMM).
pharmasol has completed the strategic merger with PharmaLex.
The UK’s NICE issued a Final Appraisal Document recommending marketing authorization for AstraZeneca’s chronic kidney disease treatment, Forxiga (dapagliflozin).
February 02, 2022
As company revenues are gaining a boost from COVID-19, the issue of pricing is being debated once more.
January 31, 2022
The draft PREVENT Pandemic Act aims to secure supply chains, expand health data collection, and support access to vital medical products
January 28, 2022
NICE has updated its Technology Appraisal Guidance TA599 for AstraZeneca’s Lokelma.
Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.
January 27, 2022
BIA and Clarivate have released new data that show there was a jump of 60% in investments into biotech and life sciences companies in the UK during 2021.
January 26, 2022
Delays in sponsors providing postapproval evidence of effectiveness for therapies benefitting from streamlined FDA regulatory pathways are generating pressure for further review and reform of the agency’s accelerated approval process.
January 21, 2022
A report by international regulators reviews the effectiveness of current COVID-19 vaccines against the omicron variant.